A phase 3, randomized, controlled, open-label study to evaluate the persistence up to 5 years of 1 or 2 doses of meningococcal conjugate vaccine MenACWY-TT given with or without 13-valent pneumococcal conjugate vaccine in 12–14-month-old children

•We report immune persistence up to 5 y post MenACWY-TT vaccination of 12–14-mo-olds.•Immune responses declined over time but were higher at 5 y vs before vaccination.•Comparable antibody persistence at Year 5 was observed with 1 or 2 MenACWY-TT doses.•Geometric mean titers were elevated in those who received 2 vs 1 dose.•No new safety concerns were identified over the study duration.